Hatch-Waxman Act

What It Means

The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is the foundational legislation governing the relationship between brand-name drug patents and generic drug competition in the United States. Named after its sponsors, Senator Orrin Hatch and Representative Henry Waxman, the law created a carefully balanced system designed to both protect pharmaceutical innovation and promote affordable generic access. The Act has two major components. First, it streamlined generic drug approval by creating the Abbreviated New Drug Application (ANDA) process, which allows generic manufacturers to rely on the safety and efficacy data from the original brand-name drug's approval rather than conducting their own clinical trials. The generic must only demonstrate bioequivalence — that it delivers the same active ingredient at the same rate and extent. Second, the Act provided patent term restoration (extension) for brand-name drugs to compensate for time lost during the FDA regulatory review process, adding up to five years to the patent term. The most consequential provision is the Paragraph IV certification process, which allows a generic manufacturer to challenge the validity or applicability of patents listed in the FDA's Orange Book. Filing a Paragraph IV certification triggers a 30-month stay of FDA approval, during which the brand-name company can sue for infringement. The first generic filer that successfully challenges the patent receives 180 days of generic exclusivity — a valuable first-mover advantage that can be worth hundreds of millions of dollars. The Hatch-Waxman framework has fundamentally shaped the pharmaceutical patent landscape and created the dynamics that drive patent cliff economics.

Frequently Asked Questions